Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Status:
Completed
Trial end date:
2019-04-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a safe, effective, and tolerable dose of PRX302 for
the treatment of low to intermediate risk prostate cancer.